RU99127290A - TARAPEUTIC AGENT FOR TREATMENT OF CACHEXIA - Google Patents

TARAPEUTIC AGENT FOR TREATMENT OF CACHEXIA

Info

Publication number
RU99127290A
RU99127290A RU99127290/14A RU99127290A RU99127290A RU 99127290 A RU99127290 A RU 99127290A RU 99127290/14 A RU99127290/14 A RU 99127290/14A RU 99127290 A RU99127290 A RU 99127290A RU 99127290 A RU99127290 A RU 99127290A
Authority
RU
Russia
Prior art keywords
treatment
cachexia
therapeutic agent
antibody
substance
Prior art date
Application number
RU99127290/14A
Other languages
Russian (ru)
Other versions
RU2227748C2 (en
Inventor
Кох САТО
Тосиаки ЦУНЕНАРИ
Кимие ИСИИ
Original Assignee
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаи Сейяку Кабусики Кайся filed Critical Чугаи Сейяку Кабусики Кайся
Publication of RU99127290A publication Critical patent/RU99127290A/en
Application granted granted Critical
Publication of RU2227748C2 publication Critical patent/RU2227748C2/en

Links

Claims (8)

1. Терапевтический агент для лечения кахексии, содержащий в качестве активного ингредиента вещество, способное ингибировать связывание между белком, родственным паращитовидному гормону человека, (PTHrP) и его рецептором.1. A therapeutic agent for the treatment of cachexia, containing as an active ingredient a substance capable of inhibiting binding between a protein related to the human parathyroid hormone (PTHrP) and its receptor. 2. Терапевтический агент для лечения кахексии по п.1, отличающийся тем, что указанное вещество является антагонистом РТНrР. 2. The therapeutic agent for the treatment of cachexia according to claim 1, characterized in that said substance is an antagonist of PTH-P. 3. Терапевтический агент для лечения кахексии по п.1, отличающийся тем, что указанное вещество является антителом против РТНrР. 3. The therapeutic agent for the treatment of cachexia according to claim 1, characterized in that the substance is an antibody against PTH-P. 4. Терапевтический агент для лечения кахексии по п.1, отличающийся тем, что указанное вещество является фрагментом антитела против РТНrР и/или его модифицированным фрагментом. 4. The therapeutic agent for the treatment of cachexia according to claim 1, characterized in that the substance is a fragment of an antibody against PTH-P and / or its modified fragment. 5. Терапевтический агент для лечения кахексии по п.3 или 4, отличающийся тем, что антитело является очеловеченным или химерным антителом. 5. The therapeutic agent for the treatment of cachexia according to claim 3 or 4, characterized in that the antibody is a humanized or chimeric antibody. 6. Терапевтический агент для лечения кахексии по п.5, отличающийся тем, что очеловеченное антитело является очеловеченным антителом 23-57-137-1. 6. The therapeutic agent for the treatment of cachexia according to claim 5, characterized in that the humanized antibody is a humanized antibody 23-57-137-1. 7. Терапевтический агент для лечения кахексии по п.3 или 4, отличающийся тем, что антитело относится к моноклональному типу. 7. The therapeutic agent for the treatment of cachexia according to claim 3 or 4, characterized in that the antibody is of the monoclonal type. 8. Терапевтический агент для лечения кахексии по пп.1 - 7, отличающийся тем, что кахексия вызвана раком. 8. The therapeutic agent for the treatment of cachexia according to claims 1 to 7, characterized in that the cachexia is caused by cancer.
RU99127290/15A 1997-05-15 1998-05-13 Therapeutic agent for treatment of cachexia RU2227748C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9/125505 1997-05-15
JP12550597 1997-05-15
JP9/194445 1997-07-18

Publications (2)

Publication Number Publication Date
RU99127290A true RU99127290A (en) 2001-09-20
RU2227748C2 RU2227748C2 (en) 2004-04-27

Family

ID=32449023

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99127290/15A RU2227748C2 (en) 1997-05-15 1998-05-13 Therapeutic agent for treatment of cachexia

Country Status (2)

Country Link
CN (1) CN1824308A (en)
RU (1) RU2227748C2 (en)

Similar Documents

Publication Publication Date Title
EP1011725A4 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
HUP9902327A3 (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
CA2211578A1 (en) Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody
EE05309B1 (en) β-Am Looid Peptide "Humanized Antibodies, Method for Their Preparation, Their Use, and Pharmaceutical Composition
DE69636760D1 (en) RECOMBINANT ANTI-CD4 ANTIBODY FOR HUMAN TREATMENT
IL105541A0 (en) Monoclonal antibodies to gp130 protein,processes for the preparation thereof and pharmaceutical compositions containing the same
PT941121E (en) LIPOPILIZED PHARMACEUTICAL PREPARATIONS, STABLE, OF MONOCLONAL OR POLYCLONAL ANTIBODIES
MXPA06003788A (en) Fully human antibodies against human 4-1bb (cd137).
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
ATE350060T1 (en) AGENTS FOR PREVENTING OR TREATING PANCREATITIS WHICH CONTAIN ANTI-IL-6 RECEPTOR ANTIBODIES AS THE ACTIVE COMPONENT
WO2004032868A3 (en) Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
HUP9802483A3 (en) Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies, as therapeutic agents for the treatment of immunological disease
RU99119493A (en) MEANS USED IN THE TREATMENT OF TUMOR LYMPHATIC TISSUE
DE69830492D1 (en) Antibodies as medicines against lymphocytic tumors (excluding myeloma)
HUP9904516A3 (en) Soluble lymphotoxin-betha receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
IT1207589B (en) COMPOSITION OF CROSS-PROTECTIVE HUMAN MONOCLONAL ANTIBODIES.
DE68920624D1 (en) Human monoclonal antibody, hybridoma that makes it, and pharmaceutical agent.
ATE235551T1 (en) LIGAND (TIE LIGAND-4) FROM TIE-2 RECEPTOR AND ITS USES
NO20024223D0 (en) Monoclonal antibodies to the human LDL receptor, their preparation and use
RU99127290A (en) TARAPEUTIC AGENT FOR TREATMENT OF CACHEXIA
CA2308007A1 (en) Enhancer for antibody to lymphocytic tumors
WO2004018519A3 (en) Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor
NZ337601A (en) Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics by inhibiting IgE expression
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
RU2001102493A (en) THERAPEUTIC AGAINST HYPERCALCEMIC CRISIS